OmniAb, Inc.
Christel Iffland has extensive work experience in the field of antibody technologies. Christel is currently working at OmniAb, Inc. as the Sr Vice President of Antibody Technologies and Vice President of Antibody Technologies. Prior to that, they held the position of Vice President of Antibody Technologies at Ligand Pharmaceuticals from 2017 to 2022. Before joining Ligand Pharmaceuticals, Christel worked at EMD Serono, Inc. where they served as the Associate Director of Antibody Technologies and Group Leader of Antibody Screening. During their time at EMD Serono, they played a significant role in directing antibody discovery processes and establishing efficient evaluation processes for antibody hits. Christel also contributed to the technical assessment of new opportunities and facilitated the full access of the Omnirat technology to Merck/EMD Serono. Christel's earlier experience includes working as a Senior Scientist II in Phage Technology at EMD Serono and as a Senior Scientist I in New Technologies at EMD Serono (former EMD Lexigen). Christel conducted post-doctoral research at the Dana-Farber Cancer Institute and Albert Einstein College of Medicine of Yeshiva University, studying the regulation of c-Myc activity and developing knockout vector constructs. Christel also worked as a graduate student at INSERM, Nice.
Christel Iffland has a diverse education history. Christel obtained a Doctor of Philosophy (Ph.D.) degree in Transcription factors, oncology, and myelomonocytic differentiation from Université Côte d'Azur between 1994 and 1997. Prior to that, they completed a Master's Degree in Isolation and characterization of hamster PPARgamma from the same university from 1992 to 1993. As for their earlier education, there is no available information about any degrees or fields of study from Lycee Carnot. In terms of certifications, Christel obtained a PMP (Project Management Professional) certification from the Project Management Institute in December 2015.
This person is not in any offices
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.